Biologic response modifiers may be candidates for accelerated approval, FDA panel agrees.
Executive Summary
BIOLOGIC RESPONSE MODIFIERS MAY BE CANDIDATES FOR ACCELERATED APPROVAL based on response rates that show meaningful benefit over existing therapies, even though biologic responses may be slower than responses with traditional cytotoxic agents, FDA's Biological Response Modifiers Advisory Committee concluded Oct. 21. The FDA meeting was convened to discuss whether biologics are appropriate for accelerated approval even though they shrink tumors by different mechanisms of action from traditional cytotoxic agents.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth